| Literature DB >> 27191617 |
Valentina Straniero1, Marco Pallavicini1, Giuseppe Chiodini1, Carlo Zanotto2, Luca Volontè2, Antonia Radaelli3, Cristiano Bolchi1, Laura Fumagalli1, Maurizio Sanguinetti4, Giulia Menchinelli4, Giovanni Delogu4, Basem Battah4, Carlo De Giuli Morghen5, Ermanno Valoti6.
Abstract
Lipophilic substituents at benzodioxane C (7) of 3-(benzodioxan-2-ylmethoxy)-2,6-difluorobenzamide improve the antibacterial activity against methicillin-resistant Staphylococcus aureus strains to MIC values in the range of 0.2-2.5 μg/mL, whereas hydrophilic substituents at the same position and modifications at the benzodioxane substructure, excepting for replacement with 2-cromanyl, are deleterious. Some of the lead compounds also exhibit good activity against Mtb. Parallel SARs to those of 3-(2-benzothiazol-2-ylmethoxy)-2,6-difluorobenzamide, well known FtsZ inhibitor, and cells alterations typical of FtsZ inhibition indicate such a protein as the target of these potent antibacterial benzodioxane-benzamides.Entities:
Keywords: 2,6-Difluorobenzamide; Antibacterial activity; Benzodioxane; FtsZ; Methicillin resistance; Mycobacterium tuberculosis; Staphylococcus aureus
Mesh:
Substances:
Year: 2016 PMID: 27191617 DOI: 10.1016/j.ejmech.2016.03.068
Source DB: PubMed Journal: Eur J Med Chem ISSN: 0223-5234 Impact factor: 6.514